For Research Use Only. Not for Clinical Use.

In recent decades, the widespread use of nanotechnology spurred the development of liposomes as drug carriers to enhance therapeutic benefits. Utilizing lipidosome based sustained release drug delivery system, drug molecules could be transported to effect sites with the protection of lipid membrane, which prolongs the half-life and reduces endogenous enzymatic hydrolysis. With rich pharmaceutical experience and well-established lipidosome based sustained release drug delivery platform, Creative Biolabs is fully competent in providing the most suitable services to global clients.

Introduction of Lipidosome Based Sustained Release Drug Delivery System

Liposomes are spherical-enclosed membrane vesicles mainly constructed with lipids which loaded with therapeutics. With its widely application in drug research, lipidosomes gradually become a pivotal biodegradable and biocompatible drug delivery and formulation platform. Lipidosome based sustained release drug delivery system was proposed to protect the drug avoiding from biological degradation, aid in the modulation of release kinetics and extension of half-life, while shielding healthy bystander tissues and cells from drug toxicity. Due to the great improvement of pharmacokinetic properties, lipidosome based sustained release drug delivery system showing a promising future in recombinant protein drugs development.

Moreover, because liposomes are typically constructed with a lipid bilayer membrane to entrap drugs inside, hydrophilic agents can be encapsulated in the aqueous core while lipophilic molecules can attach to the membrane surface. This potential to carry both hydrophobic and hydrophilic compounds has made liposomes one of the favorite research topics in drug carrier research.

Fig.1 Illustration of drug-loaded lipidosome structure (left) and encapsulation/release process (right). (Holmstrøm, 2021)

Applications of Lipidosome Based Sustained Release Drug Delivery System

Lipidosomes and derivatives exhibiting a range of biophysical and biochemical properties can be engineered to develop drug carriers for specific therapeutic applications. This potential flexibility results in wide-ranging lipid-drug compositions, which are suitable to most therapeutic proteins.

Till today, more than 15 liposome and lipid-based drug formulations are approved for human use, 6 kinds of which are treatments intended for cancers. Most of them use lipidosome based sustained release drug delivery systems to improve the pharmacokinetics by prolonging half-life. For example, lipidosome loaded insulin was administrated subcutaneously and corresponding plasma glucose levels remained low for more than 24h. Many satisfactory results have shown that lipidosome based sustained release drug delivery system will elicit significant and innovative benefits in half-life extension.

Highlights of Lipidosome Based Sustained Release Drug Delivery System

• Flexibility, widely used for many proteins.
• Suitable to both hydrophilic and hydrophobic drugs.
• Low immunogenicity and toxicity.
• Inexpensive and rapidly.

Nowadays, lipidosome based sustained release drug delivery system is widely applied in the fields of anti-tumor, anti-infection or pain management and shows great potential. For more details about our services, please feel free to contact us.

Reference

1. Holmstrøm, T.; et al. Carbohydrate derived metal chelator triggered lipids for liposomal drug delivery. Chemistry-A European Journal. 2021, 27(23), 6917-6922.